Friday, 23 Aug 2019

You are here

Trends in Inflammatory Arthritis Care in Germany

The German National Database (NDB) has reviewed their experience in the care and quality of life of inflammatory rheumatic disease patients snce 1993, showing improved use of metrics, improved outcomes and a changing profile of biologic and anti-rheumatic drug use.  

Data from the NDB was collected from 15 to 17 rheumatological institutions yearly, comprising more than 10,000 patients. About half of all NDB patients are RA, while 10% of patients have AS, 10% PsA and about 6% SLE. 

Identified trends include:

  • Increasing use of biologics, especially in rheumatoid arthritis where 30% of patients receive biologics
  • Decreasing reliance on glucocorticoids
  • Methotrexate remains as the standard therapy for rheumatoid arthritis
  • Disease activity, functional and social restrictions have decreased across all diseases
  • Work absenteeism has decreased

Epidemiologic trends - the age at onset has changed from 1994-96 to 2014-16, especially in AS and PsA, an increase in the age of onset of the disease over time was seen.  Particularly so in seronegative patients where the chage has been as much as 6 years later. The age of onset has not changed in SLE. 

Rheumatologic consultations -  have increased in all diseases, but is still low for AS at 45% in 2016 and much higher in RA (73%), SLE (71%) and PsA (66%). The mean disease duration till first contact with a rheumatologist has decreased (from  1994/2016): 1.0/0.5 years in RA; 5.0/2.1 years in AS, 2.0/0.6 years in PsA. AS remains the disorder with the longest disease duration before seeing a rheumatologist.

Trends in Drug Therapy - Biologic (dark black line below) use grew by 2016 to 28% i RA, 33% in PsA and 50% in AS. In RA and PsA, 60% of biologics are combined with a conventional synthetic DMARD, mostly methotrexate, except for AS, where biologics are used as monotherapy (84%).

Fig. 2

Overall, the outcomes and health status of many patients with rheumatic diseases in the NDB have improved.

In the digital age, there will be an increasing need for measuring instruments and the standardization of documentation systems.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

A Multidimensional Definition of Remission

A study from Leeds suggests 'multi-dimensional remission' (MDR) can be seen in one-third of RA patients achieving DAS28-remission; such patients have better patient-reported outcome measures, making it an optimal goal, especially from a patient's perspective.

Good Pregnancy Outcomes for DMARD Exposed JIA Patients

A study of pregnancy outcomes in 98 women with juvenile idiopathic arthritis (JIA) who were exposed to DMARDs shows no increased risk of major adverse pregnancy outcomes.

A total of 152 pregnancies in 98 women with JIA and 39 pregnancies involving 21 male patients as partners were reviewed. The majority had a polyarticular JIA (61%). The average age at first pregnancy was 24.1 years, and their mean disease duration was 13.8 years.

Autoantibodies Don't Disappear With Remission in RA

Immunologic remission in rheumatoid arthritis, defined as the disappearance of anti-citrullinated protein antibodies and rheumatoid factor, was seen infrequently among patients achieving sustained clinical remission and did not correlate with the disappearance of symptoms, a long-term Dutch study found.

Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease

Serologic testing is the principal means of laboratory diagnosis of Lyme disease. Current recommendations include using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay, followed by a western immunoblot assay for specimens yielding positive or equivocal results. On July 29, 2019, the Food and Drug Administration cleared several Lyme disease serologic assays with new indications for use, allowing for an EIA rather than western immunoblot assay as the second test in a Lyme disease testing algorithm. Thus, serologic assays that utilize a second EIA in place of western immunoblot assay are acceptable alternatives for the serologic diagnosis of Lyme disease.

War on RA – Part 4: Desperado – Time to Open the Gate

Do you know what the best-selling album of all time is? Could it be Bing Crosby? U2? Fleetwood Mac? AC/DC? I know, it’s Michael Jackson’s “Thriller” right? Actually it’s the Eagles Greatest Hits – it surpassed Jackson’s Thriller in August 2019 as the best-selling with a total of 36 million copies sold since it was released in 1976. Wait! Are we not Rheumatologists? Aren’t we supposed to be discussing rheumatoid arthritis?